Zacks: Brokerages Anticipate Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Quarterly Sales of $9.58 Million

Equities research analysts predict that Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) will post $9.58 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Nabriva Therapeutics’ earnings, with the lowest sales estimate coming in at $9.50 million and the highest estimate coming in at $9.65 million. Nabriva Therapeutics posted sales of $2.53 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 278.7%. The company is scheduled to announce its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Nabriva Therapeutics will report full year sales of $43.90 million for the current year, with estimates ranging from $43.29 million to $44.50 million. For the next financial year, analysts anticipate that the company will report sales of $71.73 million, with estimates ranging from $67.25 million to $76.21 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last posted its earnings results on Tuesday, March 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05). Nabriva Therapeutics had a negative net margin of 171.14% and a negative return on equity of 82.13%. The business had revenue of $9.26 million during the quarter, compared to analyst estimates of $10.30 million. During the same quarter last year, the firm earned ($1.11) earnings per share.

A number of equities research analysts recently commented on the company. StockNews.com assumed coverage on Nabriva Therapeutics in a research report on Thursday, April 28th. They set a “hold” rating on the stock. Zacks Investment Research downgraded Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th. Finally, Northland Securities cut their price target on Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 30th.

Hedge funds have recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. increased its holdings in Nabriva Therapeutics by 5,200.0% during the 3rd quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 26,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Nabriva Therapeutics by 116.3% in the 4th quarter. Renaissance Technologies LLC now owns 471,300 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 253,415 shares during the last quarter. Virtu Financial LLC acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at about $125,000. Morgan Stanley lifted its stake in Nabriva Therapeutics by 832.2% in the 2nd quarter. Morgan Stanley now owns 91,939 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 82,076 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Nabriva Therapeutics by 218.5% in the 3rd quarter. Millennium Management LLC now owns 99,151 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 68,018 shares during the last quarter. Hedge funds and other institutional investors own 1.55% of the company’s stock.

NBRV stock opened at $0.31 on Wednesday. Nabriva Therapeutics has a 1-year low of $0.28 and a 1-year high of $2.32. The firm has a market cap of $185.21 million, a P/E ratio of -0.24 and a beta of 1.57. The business’s 50 day moving average is $0.40 and its 200-day moving average is $0.63. The company has a current ratio of 3.59, a quick ratio of 2.94 and a debt-to-equity ratio of 0.08.

Nabriva Therapeutics Company Profile (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

See Also

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.